Gene expression profile in hereditary transthyretin amyloidosis: Differences in targeted and source organs

Amyloid

Volumn 21, Issue 2, 2014, Pages 113-119

  Norgren, Nina ^a   Olsson, Malin ^a   Nyström, Hanna ^a   Ericzon, Bo Göran ^b   De Tayrac, Marie ^c,d,e   Genin, Emmanuelle ^f,g   Planté Bordeneuve, Violaine ^h,i   Suhr, Ole B ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CNRS   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f French Blood Agency   (France)

^g BREST UNIVERSITY HOSPITAL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS EST   (France)

Author keywords

Adipose tissue; Familial amyloidosis; Liver tissue; PCA; Simca; V30M

Indexed keywords

PREALBUMIN; TRANSCRIPTOME;

ADIPOSE TISSUE; ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FEMALE; GENE; GENE EXPRESSION PROFILING; HEREDITARY TRANSTHYRETIN AMYLOIDOSIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FOLDING; SWEDEN; TARGET ORGAN; TTR GENE; WILD TYPE; ABDOMINAL FAT; FAMILIAL AMYLOID POLYNEUROPATHY; GENETICS; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ABDOMINAL FAT; ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PREALBUMIN; TRANSCRIPTOME;

EID: 84900532742     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2014.894908     Document Type: Article

References (36)

1. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10: 1086-97.
2. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 2001; 17: 493-503.
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10: 160-84.
4. Benson MD. Leptomeningeal amyloid and variant transthyretins. Am J Pathol 1996; 148: 351-4.
5. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget- Darpoux F, Misrahi M, Said G, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40: e120.
6. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15: 181-6.
7. Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, et al. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997; 50: 161-81.
8. Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007; 274: 1637-50.
9. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996; 35: 6470-82.
10. Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 2012; 19 Suppl 1: 78-80.
11. Ando Y, Ueda M. Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 2012; 19: 2312-23.
12. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
13. Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007; 13: 215-18.
14. Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, Nanjo H, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006; 6: 2512-15.
15. Llado L, Baliellas C, Casasnovas C, Ferrer I, Fabregat J, Ramos E, Castellote J, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010; 16: 1386-92.
16. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-92.
17. Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802-14.
18. Illumina I. Gene expression microarray data quality control. Available at: res.illumina.com/documents/products/technotes/technote-gene-expression-data- quality-control.pdf 2010.
19. Hotelling H. The generalization of Student's ratio. Ann Math Stat 1992; 2: 360-78.
20. Lee HK, Braynen W, Keshav K, Pavlidis P. ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 2005; 6: 269.
21. Suaud L, Miller K, Alvey L, Yan W, Robay A, Kebler C, Kreindler JL, et al. ERp29 regulates DeltaF508 and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) trafficking to the plasma membrane in cystic fibrosis (CF) and non-CF epithelial cells. J Biol Chem 2011; 286: 21239-53.
22. Brychzy A, Rein T, Winklhofer KF, Hartl FU, Young JC, Obermann WM. Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system. EMBO J 2003; 22: 3613-23.
23. Vainberg IE, Lewis SA, Rommelaere H, Ampe C, Vandekerckhove J, Klein HL, Cowan NJ. Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 1998; 93: 863-73.
24. Bush KT, Hendrickson BA, Nigam SK. Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. Biochem J 1994; 303: 705-8.
25. Gothel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999; 55: 423-36.
26. 2+ concentration. FEBS Lett 2004; 559: 57-60.
27. Gao Y, Thomas JO, Chow RL, Lee GH, Cowan NJ. A cytoplasmic chaperonin that catalyzes beta-actin folding. Cell 1992; 69: 1043-50.
28. Sternlicht H, Farr GW, Sternlicht ML, Driscoll JK, Willison K, Yaffe MB. The t-complex polypeptide 1 complex is a chaperonin for tubulin and actin in vivo. Proc Natl Acad Sci U S A 1993; 90: 9422-6.
29. Mkrtchian S, Sandalova T. ERp29, an unusual redox-inactive member of the thioredoxin family. Antioxid Redox Signal 2006; 8: 325-37.
30. Sousa MM, do Amaral JB, Guimaraes A, Saraiva MJ. Upregulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase- associated lipocalin, and matrix metalloproteinase- 9 in familial amyloid polyneuropathy. FASEB J 2005; 19: 124-6.
31. Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR. Why are some amyloidoses systemic? Does hepatic ''chaperoning at a distance'' prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 2012; 26: 2283-93.
32. Gomes RA, Franco C, Da Costa G, Planchon S, Renaut J, Ribeiro RM, Pinto F, et al. The proteome response to amyloid protein expression in vivo. PLoS One 2012; 7: e50123.
33. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Palladini G, Merlini G, Mauri P. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res 2013; 12: 5642-55.
34. Magalhaes J, Santos SD, Saraiva MJ. alphaB-crystallin (HspB5) in familial amyloidotic polyneuropathy. Int J Exp Pathol 2010; 91: 515-21.
35. Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Theberge R, Connors LH, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008; 7: 1570-83.
36. Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE, Warrington JA. Comparison of frozen and